常见肿瘤浸润淋巴细胞亚型对非小细胞肺癌患者预后的价值：一项荟萃分析。
Prognostic value of the common tumour-infiltrating lymphocyte subtypes for patients with non-small cell lung cancer: A meta-analysis.
机构信息
Department of Thoracic Surgery, The Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province), Kunming, Yunnan, China.
出版信息
PLoS One. 2020 Nov 10;15(11):e0242173. doi: 10.1371/journal.pone.0242173. eCollection 2020.
BACKGROUND
Many previous studies have revealed that tumour-infiltrating lymphocytes (TILs) are significantly associated with prognosis in various tumours. However, this finding remains controversial in non-small cell lung cancer (NSCLC). We performed this meta-analysis systematically to evaluate the prognostic value of TILs in NSCLC.
METHODS
The references were collected by searching the PubMed, EMBASE and Web of Science databases. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were summarized using random or fixed effects models to evaluate the association between TILs and NSCLC survival outcomes.
RESULTS
A total of 45 interrelated studies were eligible that included 11,448 patients. Pooled analysis showed that a high density of TILs indicated a better overall survival (HR = 0.80, 0.70-0.89) and progression-free survival (HR = 0.73, 0.61-0.85) for patients with NSCLC; a high density of CD3+ TILs in the tumour nest indicated a better overall survival (HR = 0.84, 0.69-0.99) and disease-specific survival (HR = 0.57, 0.34-0.80); a high density of CD4+ TILs in the tumor nest indicated a favourable overall survival (HR = 0.86, 0.76-0.96); a high density of CD8+ TILs indicated a favourable overall survival (HR = 0.995, 0.99-1.0), progression-free survival (HR = 0.52, 0.34-0.71), disease-free survival (HR = 0.64, 0.43-0.85), relapse/recurrence-free survival (HR = 0.42, 0.18-0.67) and disease-specific survival (HR = 0.56, 0.35-0.78); and a high density of CD20+ TILs in the tumour nest indicated a favourable overall survival (HR = 0.65, 0.36-0.94). However, a high density of Foxp3+ TILs in the tumour stroma indicated a worse relapse/recurrence-free survival (HR = 1.90, 1.05-2.76) in NSCLC.
CONCLUSIONS
Our meta-analysis confirmed that high densities of TILs, CD3+TILs, CD4+TILs, CD8+TILs and CD20+TILs in the tumour nest are favourable prognostic biomarkers for patients with NSCLC, and Foxp3+TILs in the tumour stroma are a poor prognostic biomarker.
背景
许多先前的研究表明，肿瘤浸润淋巴细胞（TILs）与各种肿瘤的预后显著相关。然而，这一发现在非小细胞肺癌（NSCLC）中仍存在争议。我们进行了这项荟萃分析，以系统地评估 TILs 在 NSCLC 中的预后价值。
方法
通过检索 PubMed、EMBASE 和 Web of Science 数据库收集参考文献。使用随机或固定效应模型汇总汇总风险比（HRs）和 95%置信区间（CIs），以评估 TILs 与 NSCLC 生存结局之间的关联。
结果
共纳入 45 项相关研究，包含 11448 名患者。荟萃分析显示，TILs 密度高表明 NSCLC 患者的总生存期（HR=0.80，0.70-0.89）和无进展生存期（HR=0.73，0.61-0.85）更好；肿瘤巢中 CD3+TILs 密度高表明总生存期（HR=0.84，0.69-0.99）和疾病特异性生存期（HR=0.57，0.34-0.80）更好；肿瘤巢中 CD4+TILs 密度高表明总生存期（HR=0.86，0.76-0.96）良好；CD8+TILs 密度高表明总生存期（HR=0.995，0.99-1.0）、无进展生存期（HR=0.52，0.34-0.71）、无病生存期（HR=0.64，0.43-0.85）、无复发生存期（HR=0.42，0.18-0.67）和疾病特异性生存期（HR=0.56，0.35-0.78）较好；肿瘤巢中 CD20+TILs 密度高表明总生存期（HR=0.65，0.36-0.94）良好。然而，肿瘤基质中 Foxp3+TILs 密度高表明 NSCLC 患者的无复发生存期较差（HR=1.90，1.05-2.76）。
结论
我们的荟萃分析证实，肿瘤巢中 TILs、CD3+TILs、CD4+TILs、CD8+TILs 和 CD20+TILs 密度高是 NSCLC 患者的有利预后生物标志物，而肿瘤基质中 Foxp3+TILs 是不良预后生物标志物。
Zotero 插件